LO LOESTRIN FE
LOE Approachingnorethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate
NDAORALTABLET
Approved
Oct 2010
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Data completeness
5/8 — Partial
LO LOESTRIN FE (norethindrone acetate and ethinyl estradiol, ethinyl estradiol and ferrous fumarate) is ovulation. First approved in 2010.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LO LOESTRIN FE is an oral contraceptive combining norethindrone acetate and ethinyl estradiol with ferrous fumarate (iron supplement). It prevents ovulation and is indicated for contraception in women of childbearing potential. The ultra-low dose formulation (1 mg norethindrone acetate / 10 mcg ethinyl estradiol) offers reduced hormone exposure while maintaining efficacy.
$0.001BPart D
LOE ApproachingDeclining
2.7 years to LOEDeclining commercial trajectory with minimal Part D claims signals a shrinking brand team and shift toward legacy product management.
Mechanism of Action
ovulation.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~3 years — strategic planning for patent cliff underway
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.